![](https://cdn.sanity.io/images/0vv8moc6/pharmacytimes/91a5d4a6bdeace15648505e2118608d577156eb2-5000x3338.jpg?fit=crop&auto=format)
SELECT Trial: Semaglutide Improves Glycemic Control For Patients at High Risk of Cardiovascular Disease
At the ADA 84th Scientific Sessions, new data from the SELECT (NCT03574597) trial shows semaglutide’s effect on glycemia, inflammation, and heart failure, demonstrating that the drug improved glycemic control in those at high risk of cardiovascular disease …